China SXT Pharmaceuticals, Inc.
SXTC Healthcare Drug Manufacturers Specialty & Generic
China SXT Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, down 34.6% from fiscal 2025.
Follow SXTC
China SXT Pharmaceuticals, Inc. (SXTC) EV/Sales
As of 16 October 2026, China SXT Pharmaceuticals, Inc. (SXTC) trades at a EV/Sales of −5.9×. Over the past ten years it has ranged from −5.9× (October 2026) to 0.0× (March 2020) — the current reading is the lowest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | −5.9× | — |
| FY2025 | −3.8× | — |
| FY2024 | −2.1× | — |
| FY2023 | −3.0× | — |
| FY2022 | −1.8× | — |
| FY2021 | −1.3× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2023 | 212,980× | 70.41% |
| Sep 2022 | 124,981× | 10,724.56% |
| Mar 2022 | 1,155× | (96.27%) |
| Sep 2021 | 30,990× | (28.11%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SXTC China SXT Pharmaceuticals, Inc. | −5.9× |
| SBFM Sunshine Biopharma, Inc. compare | −0.3× |
| LSDIF Lucy Scientific Discovery Inc. compare | n/m |
| AKAN Akanda Corp. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| IMCC IM Cannabis Corp. compare | 0.0× |
| PTPI Petros Pharmaceuticals, Inc. compare | 0.4× |
| NEPTF Neptune Wellness Solutions Inc. compare | 1.1× |
| BTAIQ BioXcel Therapeutics, Inc. compare | 228× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)